Conventional Surgery + Intensity-Modulated Radiation Therapy + Quality-of-Life Assessment + Trametinib + PEMBROLIZUMAB + DABRAFENIB for thyroid carcinoma, anaplastic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Dec 2020: Trial registered, NCT04675710
  2. 24 Jun 2021: Trial started, NCT04675710

The trials

NCT04675710: Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

State
Under way
Phase
Phase 2
People
30 planned
Started
24 Jun 2021
Primary completion
30 Oct 2028
Arms
Treatment (dabrafenib, trametinib, pembrolizumab)
Results
None posted
  1. 19 Dec 2020: Trial registered
  2. 24 Jun 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.